Abstract:
The invention relates to a method for determining homocysteine concentration in samples in which homocysteine is condensed using an enzyme cystathionine &bgr; sythase to form cystathionine. Pyruvate and/or ammonia are released from cystathionine by action of an enzyme, cystathionine &bgr; lyase, and homocysteine is regenerated. The release of pyruvate and/or ammonia can be correlated to the concentration of homocysteine present in the sample.
Abstract:
The invention relates to a pharmaceutical composition comprising an SGLT2 inhibitor and a PPARγ agonist which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.
Abstract:
The invention relates to a method for determining homocysteine concentration in samples in which homocysteine is condensed using an enzyme cystathionine &bgr; sythase to form cystathionine. Pyruvate and/or ammonia are released from cystathionine by action of an enzyme, cystathionine &bgr; lyase, and homocysteine is regenerated. The release of pyruvate and/or ammonia can be correlated to the concentration of homocysteine present in the sample.